Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2019

View Archived Issues

CJ-15314: a novel JAK1 inhibitor for the treatment of rheumatoid arthritis

A-166, a new anti-HER2 antibody-drug conjugate for advanced/metastatic solid tumors: phase I results

Lineage Cell Therapeutics provides update on phase I/IIa SCiStar study of OPC-1

Interim analysis of phase II data for licogliflozin in NASH

Preliminary phase I data presented for DCC-3014

Phase IIa data for IONIS-HBVRx in treatment-naive chronic HBV patients

STAT3-targeting PROTAC proof of principle for 'undruggables'

Novel PDX mouse models of gastric cancer

Effluent DcR2 is a new marker of peritoneal fibrosis in patients with peritoneal dialysis

Differentially expressed sncRNAs in patients with T1D at risk of progressive renal disease

Promising phase I/Ib data presented for the novel anti-CD73 antibody CPI-006

First placebo-controlled trial in renal scleroderma shows positive results for zibotentan

Fujifilm initiates phase I trial of FF-10850 in advanced solid tumors

Double-duty CD4+ T cells may hold key to longevity

3SBio and Verseau select VTX-0811 as first licensed program under immuno-oncology partnership

Phase II study of KarXT for acute psychosis in schizophrenia meets primary endpoint

Clinical study of [131I]omburtamab advances in desmoplastic small round cell tumors

A placebo-controlled, first-in-human phase I study of the anti-ADAMTS-5 nanobody M-6495

Janssen Pharmaceutica patents androgen receptor antagonists

Bristol-Myers Squibb divulges TLR7 agonists

Ribon Therapeutics describes TIPARP inhibitors

Landsteiner Genmed identifies CAPN1 inhibitors

Merck & Co. divulges nicotinic acetylcholine alpha7 receptor PAMs

U.K. clearance for phase I/II study of TX-200 in kidney transplantation

BioArctic to end SC-0806 development in complete spinal cord injury based on interim phase I/II data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.